Fibronectin targeted IFNγ Development Service
Creative Biolabs offers end-to-end development of robust and clinically translatable Fn-IFNγ fusion proteins, designed to bypass the systemic toxicity that has historically plagued cytokine-based cancer therapies. We provide functionally verified candidates that serve a dual therapeutic purpose: immune cell priming and structural disruption of the tumor microenvironment (TME). Our approach focuses on targeting oncofetal fibronectin variants in the TME for precise localization and engineering IFNγ for sustained, localized activation to maximize anti-tumor immune responses. This strategy enhances efficacy and provides a profoundly improved safety profile.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The Target: Oncofetal Fibronectin (Fn) - The Structural Achilles' Heel of the TME
Solid tumors depend on a dense, abnormal extracellular matrix (ECM). The extra domain A (EDA) and extra domain B (ED-B) of Fibronectin are specific splice variants, serving as hallmarks of pathological ECM remodeling. These oncofetal proteins are nearly undetectable in healthy adult tissues but highly expressed in the tumor stroma and neovasculature of aggressive solid cancers, offering superior specificity. Their structural stability as non-shedding ECM components provides a high-density scaffold for deep agent retention. Oncofetal Fn's presence correlates with high-grade malignancy, EMT, and therapy resistance, making it an optimal therapeutic anchor for disrupting pro-tumorigenic pathways.
Key Deliverables and Solutions You Can Expect
Optimal Targeting Moiety
Delivery of high-affinity scFv binders specific to the chosen fibronectin domain (EDA-Fn or ED-B Fn) for your target indication.
Maximized Therapeutic Index
Functionally validated, detuned IFNγ variants engineered to exhibit significantly reduced affinity for systemic IFNγR, translating to minimal off-target effects and superior safety profiles in pre-clinical studies.
Dual-Action Efficacy
Candidates proven to induce MHC-I upregulation on tumor cells (immune priming) and reduce α-SMA expression in CAFs (stromal deactivation).
Pre-Clinical Readiness
Data supporting enhanced tumor retention, favorable pharmacokinetics, and superior anti-tumor efficacy compared to untargeted, wild-type IFNγ.
Contact our experts today for a confidential, no-obligation technical consultation.
Workflow: Comprehensive Path to an Fn-IFNγ Lead Candidate
We follow a modular, transparent, and comprehensive five-stage workflow, ensuring quality and functional validation at every step.
Why Choose Us?
Creative Biolabs is the industry leader in targeted cytokine therapy, with two decades of expertise in ECM biology and molecular engineering. Our unique, dual-mechanism approach ensures superior performance by addressing systemic toxicity and insufficient tumor retention. Through proprietary attenuation engineering, we precisely modify IFNγ sequences to reduce binding affinity for systemic IFNγR, minimizing side effects and enhancing tumor-site dosing, as validated by published data. Our dual-mechanism therapeutic design enables Fn-IFNγ agents to activate immune priming by upregulating MHC-I and disrupt the stroma by suppressing CAF activity and angiogenesis, crucial for "cold" tumors. This strategy, backed by clinical validation of the fibronectin target, ensures a robust path to IND submission.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: How does Creative Biolabs ensure that targeting Fn splice variants truly prevents off-target toxicity, given that normal tissues contain Fn?
A1: Our targeting moieties are exclusively generated and screened to be highly specific to these oncofetal domains, which are markers of pathological tissue remodeling and neovasculature, ensuring minimal binding and toxicity outside the TME.
Q2: If the IFNγ is "detuned" to reduce systemic binding, will it still be potent enough when localized at the tumor site?
A2: Absolutely. The goal of attenuation is to reduce the low-affinity systemic IFNγR binding that causes trapping and toxicity, while maintaining the high local concentration required for efficacious signaling at the tumor site.
Q3: How does Creative Biolabs' Fn-targeting strategy compare to targeting T-cell receptors or other cell-surface antigens for cytokine delivery?
A3: Targeting the ECM ensures stable, high-density therapeutic agent accumulation, overcoming T-cell/tumor cell-surface target heterogeneity and internalization. This leads to longer therapeutic windows and deeper tissue penetration.
Customer Reviews
-
Superior Pharmacokinetics
The detuned IFNγ yielded an improved therapeutic index critical for our chronic dosing regimen, allowing us to maintain sustained efficacy without dose-limiting toxicities. – Dr. Emi*** Y
-
Dual-Action Efficacy
We required a dual-action agent capable of addressing both the immune desert and the physical barrier of our desmoplastic model. The ability of the targeted IFNγ to not only activate T cells but also demonstrate quantifiable α-SMA reduction in CAFs was a breakthrough. - Dr. Pat*** L
Related Services
Creative Biolabs offers a full suite of services complementary to our Fn-IFNγ development platform, helping you build a comprehensive TME-targeting therapeutic strategy.
Chemokine Production Measurement Service
Creative Biolabs offers comprehensive chemokine production assays (qPCR, gene array, blot, flow cytometry, WB, ELISA) to identify ideal targets, manipulate intratumoral pathways, and improve immunotherapy responses in cancer.
Learn More →
Process Development Service
Creative Biolabs offers end-to-end therapeutic antibody and protein services, from discovery (scFv, Fab, IgG) to purification and multi-gram manufacturing in HEK/CHO cells.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs provides the expertise and advanced technology necessary to design and deliver robust, clinically viable Fn-IFNγ fusion proteins. By strategically targeting the oncofetal fibronectin scaffold and employing our proprietary attenuation engineering, we ensure that your immunocytokine candidate achieves unparalleled local potency and safety, maximizing the chances of success against solid tumors.
Ready to revolutionize your solid tumor immunotherapy program? Our team of ECM biology and cytokine engineering specialists is here to guide you. Discuss your project requirements and receive a customized technical proposal today.
